Genomic landscape of pathogenic mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian colorectal cancer.

BACKGROUND: Colorectal cancer (CRC) needs several mutations to occur in various genes, and can vary widely in different individuals; hence it is essential to be discovered in a specific population. Until recently, there has been no known study describing APC, TP53, PIK3CA, KRAS, and MLH1 of CRC in Indonesian population. This study describes the nature and location of mutation in CRC patients treated at three different hospitals in Jakarta.
METHODS: This descriptive study was conducted on CRC patients who underwent neoadjuvant, surgical, and adjuvant therapy at RSCM, RSKJ, and MRCCC in 2017-2018. DNA analysis was performed using next-generation sequencing and aligned against GRCh38. The pathogenic variant was identified using ACMG classification and FATHMM score. Data related to behavior and survival were collected from medical records.
RESULTS: Twenty-two subjects in which APC, TP53, and PIKCA were mutated. KRAS mutation occurred in 64%, while MLH1 in 45%. There were five mutation types: nonsense, missense, frameshift, splice-site, and silent mutation. There are four groups of co-occurring mutations: APC, TP53, PIK3CA (triple mutation/TM) alone; TM+KRAS; TM+MLH1; and TM+KRAS+MLH1, presenting different nature and survival.
CONCLUSION: Indonesia has a distinct profile of pathogenic mutation, mainly presenting with locally-advanced stage with various outcomes and survival rate.

Introduction

Colorectal cancer has been known as one of the most well-studied malignancies. Its dynamic and heterogeneity are characterized by many interconnecting molecular etiopathogeneses exhibiting different behavior inter and intratumor [1-5]. Based on recent biomolecular studies, genetic and epigenetic analysis can evaluate the nature of the tumor, hence, able to predict heredity, progressivity, recurrency, response to therapy, and even survival rate. Those variables cannot be estimated by the AJCC staging system alone. For this reason, precision medicine rooting in the genomic profile of each individual is starting to advance.

Colorectal malignancy, which involves at least three or four genetic mutations, is feasible for next-generation sequencing methods [2, 6]. Two of the three most common carcinogenic pathways are chromosomal and microsatellite instability [7-10]. Five genes which frequently involved are APC, TP53, KRAS, PIK3CA, and MLH1. Different groups of age, gender, and geographic location have different variations of mutation and genes involved, so that study on a specific population is essential in advancing precision medicine [11]. Until recently, there has been no publication providing the genomic landscape of colorectal cancer in Indonesian population. This study aims to analyze the genomic profile of colorectal cancer in Indonesia.

Methods

This is a descriptive study in patients with colorectal malignancies who underwent surgery, chemoradiation, chemotherapy at RSCM, RSKJ, and MRCCC in 2017–2018 whose tumor tissue specimens were still stored correctly in the form of formalin-fixed paraffin-embedded (FFPE). This study has been reported in line with STROCSS criteria [12].

Sample preparation

The Department of Medical Chemistry, Faculty of Medicine, Universitas Indonesia at Bioinformatics Core Facility of Indonesia Medical Education and Research Institute (IMERI) performed all sequencing preparation.

DNA extraction was performed using the QIAamp DNA FFPE Tissue Kit. The quality of extracted DNA was evaluated using an absorbance ratio of 260 nm to 280 nm (A260/A280) and 260 nm to 230 nm (A260/A230). The purity criterion for samples with the A260/A280 ratio is within the range of 1.8–2.0, and the A260/A230 ratio is within 2.0–2.2. After the purity criterion was fulfilled, sequencing was done utilizing AmpliSeq Cancer HotSpot Panel v2 for Illumina. Results in FASTQ format were quality-checked with FASTQC (v.0.9.5; http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and aligned against Genome Reference Consortium Human Reference 38 (GRCh38). Variant calling was done using LoFreq, annotated with SNPEFF, and filtered with SNPSift. Annotation results were stored in a variant call format (VCF) file.

Retrieval of VFC files fulfilling inclusion and exclusion criteria

Inclusion criteria: FFPE samples fulfilling DNA purity criterion and showing PASS status in FASTQC

Exclusion criteria: none

Data filtering based on estimation of putative impact or deleteriousness showing “HIGH”.

Identification of single nucleotide variant (SNV) and synchronization with three databases

ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/)

COSMIC (https://cancer.sanger.ac.uk/cosmic)

The Ensembl project (https://asia.ensembl.org/info/index.html)

Identification of somatic effect based on American College of Medical Genetics (ACMG) classification and Functional Analysis through Hidden Markov Models (FATHMM) score.

Selection of SNVs meeting pathogenic criteria (ACMG pathogenic variant or FATHMM score ≥ 0,7 or both.

Identification of SNVs of APC, TP53, PIK3CA, KRAS, and MLH1

Matching samples’ numbers and medical record data

Ethical approval

The Ethics Committee of the Faculty of Medicine, Universitas Indonesia–RSUPN Cipto Mangunkusumo regarding the Protection of human rights and welfare in medical research, has carefully reviewed the research with registry number: KET-445/UN2.F1/ETIK/PPM.00.02/2021. All procedures of Ethical Approval are performed in accordance with ICH-GCP standard procedure. All data were fully anonymized and Ethics committee waived the requirement of the informed consent.

Results

Patients characteristics

Twenty-two samples were collected in accordance with the sample preparation procedures mentioned above. Among these samples, 41% (9/22) were diagnosed with stage 3b, of which 7 were elective cases. Fifty-nine percent (13/22) had lymphovascular invasion, of which one was diagnosed with stage 2A, and 12 were in stage 3B-4C.

Pathogenic mutation mapping in whole chromosomes

There were pathogenic mutations in almost all somatic chromosomes except 6, 9, 14, 16, 21, and 22, which involved 25 genes and 641 SNV (Table 1). Three mutation types were identified, i.e., synonymous (silent mutation), nonsynonymous (nonsense, missense, and frameshift), and splice-site mutation.

Table 1

Pathogenic mutation mapping.

Chr	1	2			3				4	5	7		8	10			11	12	13	15	17	18	19	20		Total Genes	Total SNVs
Gene	a	b	c	d	e	f	g	h	i	j	k	l	m	n	o	p	q	r	s	t	u	v	w	x	y
Pts
1(1)					2		2		1	1		2						2	1		4	5	1			10	21
2(3)					1	1	1		1	3	1			1	1	1			4	1	10	1		1	1	15	29
3(6)	1					2	1		2	3	1	1							1		7					9	19
4(14)	1	1					1		1	3									1		3		1			8	12
5(15)	1		2		1		1	1		2	1				1				1		4	2				11	17
6(16)					1		2			2	1				1				1		4	1				8	13
7(19+19b)			2			2	2		1	4	2	1					1	2	4	1	14	2	1	1		15	40
8(20)				1	2	1	1		3	2								1	5	1	9	2	1			12	29
9(22)	1				1		3		2	1											9	1			1	8	19
10(23)					1	2	2			1		1							4		4	1		1		9	17
11(29)			1			1	1			3	2	1			1			1	1		4		1	1		12	18
12(34)	1	1			2	1	2			6	1	2	1	1		1	1		3		10	1	1		1	17	36
13(3737)	1	1				1	2		2	5	2	2			2			1	3		10	4		1	1	15	38
14(9)	1				1		1			3	1	1					1	1	3		7	1	2			12	23
15(11)	1		1		1	1	3			6	1	2		1	1			2	3		9	4	1			15	37
16(12)	1	2	1		3	2	2	1	1	7	5	2	1			1	1	4	6		9	4		1		19	55
17(13)			1		2		4		1	3	3	1			2	1		1	4		17	4	1	1		14	46
18(14)		1	1		2		2		3	3	1			1	1		1	1	4	1	6	5		1	1	17	35
19(16)	1		1	1	1		2		1	3	1	1	1					2	3	1	14	2	2			16	37
20(17)					2		1		1	1		1						1	4		13	6				9	30
21(18)					2		3		1	4	2	1		1			1	1	4		12		1	1		13	34
22(19a)			1		1		2	1	2	1	1	2	1		2			1	6		10	3	1	1		16	36
Total Patients	10	5	9	2	17	10	22	3	15	22	16	15	4	5	9	4	6	14	21	5	22	18	12	10	5		641

a. NRAS; b. ALK; c. IDH1; d. ERBB4; e. VHL; f. MLH1; g. PIK3CA; h. CTNNB1; i. KIT; j. APC; k. BRAF; l. EGFR; m. FGFR1; n. RET; o. PTEN; p. FGFR2; q. ATM; r. KRAS; s. RB1; t. IDH2; u. TP53; v. SMAD4; w. STK11; x. SRC; y. GNAS

Pathogenic mutation mapping of APC, TP53, PIK3CA, KRAS, and MLH1

Two APC pathogenic mutations occurred concurrently (nonsense and missense) in 1 patient. TP53 also had five coherent mutations in 1 patient (nonsense, missense, frameshift, silent, and splice-site) and only 3 of 22 patients had missense mutation. Only 1 type of pathogenic mutation occurred in MLH1 (nonsense) and PIK3CA (missense). Singular KRAS mutation occurred in 10 patients (8 missense and 2 silent), and multiple mutations occurred in 4 patients (Table 2).

Table 2

Pathogenic mutation mapping of 5 genes.

Gene	n = 22
MLH1		*	*				*	*		*	*	*	*		*	*
PIK3CA	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+
APC	*	*	*	*	*	*	*	*	*	*	*	*+	*	*	*	*	*	*	*	*	*	*
KRAS	+&						*&	+			+		&	+	+	+&	+	+	+&	&	+	+
TP53	+%	+%	+*	+	+#	+*	+*#	+*%	+*%	+	+*	+*	+*#	+%	+*&	+	+*%	+*%	+*	+*&	+%	+*%#
Sample	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22

*Nonsense; +Missense; #Frameshift; %Splice-site; &Silent; None

Co-occurring mutations in more than three genes were presented in all subjects. A combination of triple mutation (APC, TP53, PIKCA) occurred in 4 of 22 patients. A combination of quintuple mutation (APC, TP53, PIKCA, KRAS, MLH1) occurred in 6 of 22 patients (Table 3).

Table 3

Subjects with co-occurring mutation.

Co-occurring mutation	Number of subjects
APC + TP53 + PIK3CA + KRAS + MLH1	6
APC + TP53 + PIK3CA + KRAS	8
APC + TP53 + PIK3CA + MLH1	4
APC + TP53 + PIK3CA	4
Total	22

APC mutation

Gene mutation occurred in 100% of subjects with 17 SNVs (16 missense and 1 nonsense). Mutation cluster regions (MCR) were located in exon 14–17. Median of SNV frequency was 4 (range 1–10). The most frequently occurred SNV was Q879* (Table 4).

Table 4

APC mutation.

Nonsense mutation			Missense mutation
SNV (n = 16)			SNV (n = 1)
Nucleotide change	Codon	Number (n = 22)	Nucleotide change	Codon	Number (n = 22)
C>T	Q879*	10	C>T	T1493M	1
	Q1123*	8
	R876*	6
	R1114*	6
	Q1367*	6
	Q1517*	5
	Q1095*	4
	Q1303*	4
	Q1096*	4
	Q1378*	4
	Q1291*	2
	Q1294*	2
	Q1429*	2
	Q1444*	1
	R1450*	1
	Q1469*	1

KRAS mutation

In this study, KRAS mutation occurred in 14 of 22 patients (63,6%). Nine SNVs were identified in 3 types of mutations, i.e., missense, nonsense, and silent. The nonsense mutation causes termination of codon 22, missenses occurred in 6 codons, and silent in 2 codons. The most frequently occurred SNVs are T20 = in 4 subjects, A146T, and P34L in 3 subjects (Table 5).

Table 5

KRAS mutation.

Nonsense mutation			Missense mutation			Silent mutation
SNV (n = 1)			SNV (n = 6)			SNV (n = 2)
Nucleotide change	Codon	Number (n = 14)	Nucleotide change	Codon	Number (n = 14)	Nucleotide change	Codon	Number (n = 14)
C>T	Q22*	1	G>A	A146T	3	G>A	T20 =	4
				V14I	2	C>T	G13 =	3
				G13S	2
				A59T	1
			C>T	P34L	3
				T58I	2

TP53 mutation

TP53 mutation also occurred in 100% subjects in with 65 SNVs categorized into 5 types of mutations i.e. (1) missense, (2) nonsense; (3) frameshift; (4) silent; (5) splice-site. In missense mutation, the two most frequent SNVs are M237I and C238Y. In nonsense mutation, the two most frequent SNVs are R342* and R213* (6 of 22 patients) (Tables 6 and 7).

Table 6

TP53 mutation.

Missense mutation
SNV (n = 49)
Nucleotide change	Codon	Number (n = 22)	Nucleotide change	Codon	Number (n = 22)
G>A	M237I	8	A>G	M237V	2
	C238Y	7		H214R	2
	R248Q	6		K132E	1
	C277Y	6		Q192R	1
	G245S	6		N235D	1
	G245D	5		Y236C	1
	G244D	4	C>T	S127F	6
	V197M	4		R248W	6
	R213Q	4		R282W	5
	R175H	4		T256I	4
	E258K	4		A138V	4
	R273H	4		P152L	4
	R196Q	3		L194F	4
	C135Y	3		P250L	3
	G154S	3		R273C	3
	R280K	3		P152S	2
	R267Q	2		T155I	2
	E285K	2		P278L	2
	E286K	1		R175C	1
	R290H	1	G>C	V272L	1
	C275Y	1	T>C	L755S	1
	G266E	1		F134L	1
	R249K	1		C238R	1
	R156H	1		L252P	1
	R158H	1

Table 7

TP53 mutation (cont.).

Nonsense mutation			Frameshift mutation			Splice-site mutation			Silent mutation
SNV (n = 6)			SNV (n = 1)			SNV (n = 6)			SNV (n = 3)
Nucleotide change	Codon	Number (n = 22)	Nucleotide change	Codon	Number (n = 22)	Nucleotide change	Codon	Number (n = 22)	Nucleotide change	Codon	Number (n = 22)
C>T	R342*	6	G>A	M1?	4	c.919+1G>A	p.?	4	C>T	G244 =	1
	R213*	6				c.673-1G>A	p.?	3	G>A	V272 =	1
	R196*	5				c.560-1G>A	p.?	3	C>A	R213 =	1
	Q136*	4				c.994-1G>A	p.?	2
	Q165*	1				c.559+2T>C	p.?	1
G>A	W91*	2				c.376-2A>G	p.?	1

PIK3CA mutation

Mutation of PIK3CA occurred in exons 2, 5, 7, 8, 10, 19, and 21. In this study, PIK3CA missense mutations were identified in all subjects. Median of SNV frequency was 4 (range 1–16). The most frequently occurred SNV was G914R (Table 8).

Table 8

PIK3CA mutation.

Missense mutation
SNV (n = 9)
Nucleotide change	Codon	Number (n = 22)
G>A	G914R	16
	V71I	7
	R88Q	5
	G1049S	4
	R398H	2
	E542K	1
C>T	H1047Y	3
A>G	H1047R	2
T>A	N345K	1

MLH1 mutation

MLH1 mutation occurred in 10 of 22 (45,45%) subjects. The nonsense mutation occurred in exon 9–13, causing termination in 4 codons. The most frequently occurred SNV was Q391* (Table 9).

Table 9

MLH1 mutation.

Nonsense Mutation
SNV (n = 4)
Nucleotide change	Codon	Number (n = 10)
C>T	Q391*	6
	Q382*	5
	Q409*	2
	Q398*	1

Biological behavior of malignancy with co-occurring mutation (Table 10)

Co-occurring mutations of APC, TP53, PIK3CA, and KRAS were identified in 8 patients with an average age of 48,5 years old, with locally-advanced stage (n = 5), located in the rectum (n = 6), well-differentiated (n = 6), and positive lymphovascular invasion (n = 5).

Co-occurring mutations of APC, TP53, PIK3CA, and MLH1 were identified in 4 patients, with an average age of 52,3 years old, with locally advanced stage (n = 3), located in the rectum (n = 3), without lymphovascular invasion.

Quintuple mutations were identified in 6 patients, dominated by older age, locally-advanced stage, well-differentiated, positive lymphovascular invasion, and located in the rectum or left colon.

Survival

Patients with co-occurring mutations of APC, TP53, PIK3CA, and MLH1 (cluster 2) had the longest median life expectancy (1197 days) compared to cluster 1 with the shortest median life expectancy (577 days) (Table 3, Fig 1).

Fig 1

Median life expectancy in days.

Fifty percent of subjects of cluster 1 and 3 were deceased in less than six months after therapy; in cluster 4, 50% of subjects were deceased before month 15. Cluster 2 can survive up to 30 months after therapy and only 1 patient deceased afterward. Cluster 1 and 4 show the highest mortality rate with the highest number of deceased patients in the shortest period compared to other clusters (Fig 2).

Fig 2

Survival rate based on co-occurring mutation.

Other findings

Early recurrence (<5 years) occurred in 2 patients of cluster 4, of which 1 patient underwent neoadjuvant chemoradiation and adjuvant chemotherapy (MFOLFOX6), and another was given XELOX after surgery. Both patients have a disease-free interval of 15 months.

One patient was given anti-EGFR therapy (cetuximab) + MFOLFOX6. The patient’s PCR result for KRAS was wild-type. There is no therapeutic response data due to the patient’s death during midcycle (127 days after surgery). This patient was included in cluster 1 (with KRAS mutation) and had EGFR mutation (rs121913467).

One patient was given anti-VEGF therapy (bevacizumab) + MFOLFOX6 after being diagnosed with local recurrence after 1-year of oral capecitabine and had a complete response to bevacizumab. This patient was included in cluster 2 with noted BRAF mutation (rs121913353).

Two of 22 patients had a family history of malignancy (Table 11). Germline mutation of STK11 was identified in one patient with a family history of colon cancer. Meanwhile, two germline mutations of TP53 were identified in another patient with a family history of breast cancer.

Table 11

Patients characteristics.

Variables		Numbers	%
Age	< 50 y.o.	9	41
	≥50 y.o.	13	59
Gender	Male	13	59
	Female	9	41
Death	Yes	11	50
	No	11	50
Grade	Well	13	59
	Moderate	6	27
	Poor	3	14
Stage	1	2	9,1
	2A/B/C	5/1/-	22,7/4,5/-
	3A/B/C	-/9/-	-/40,9/-
	4A/B/C	2/1/2	9,1/4,5/9,1
Lymphovascular invasion	Yes	13	59
	No	9	41
Tumor location	Group 1	3	14
	Group 2	4	18
	Group 3	15	68
Perioperative management	None	13	59
	Neoadjuvant chemoradiation	-	-
	Adjuvant chemotherapy	7	32
	Neoadjuvant chemoradiation + adjuvant chemotherapy	2	9
Family history of cancer	Colon cancer	1	9
	Breast cancer	1
Average interval from diagnosed to death		259 days (3–882)

Group 1: Caecum to two-thirds proximal of the transverse colon; Group 2: One-third distal of the transverse colon to sigmoid; Group 3: Rectum to anus.

Discussion

Colorectal cancer (CRC) patients in Indonesia are dominated by males (59%), more than 50 years old (59%), with well-differentiated (59%), stage 3B (40,9%), located in the rectum (68%). Recently, the incidence of CRC in young adults increased by 1,4% per year, influenced by obesity and a sedentary lifestyle [13]. High percentage of the locally-advanced stage on hospital admission can be caused by low educational level about CRC risk factors and importance of screening, especially in individuals with a family history of malignancy. The intricate system of national health insurance also has a role in slacking patients with unspecific complaints to see doctors before having an apparent disorder and getting worse. These are several reasons that cause a delay in the diagnosis and management of CRC.

The heterogeneous and dynamic nature of the CRC is related to its overlapping pathways of carcinogenesis. There are four principles of neoplasia in CRC, (1) colorectal tumors arise due to the activation of proto-oncogene mutations into oncogenes and inactivation of tumor suppressor genes [14]; (2) at least mutations in any 4–5 genes are required for malignant formation; (3) accumulation of numbers is more important than the sequence of mutations in determining tumor biologic behavior; (4) the mutated tumor suppressor gene continues to express the phenotype without loss of heterozygosity [2].

The theory of colorectal neoplasia, namely adenoma-carcinoma sequence (ACS), states that the presence of an adenoma must precede the formation of colorectal carcinoma [1, 2]. Mutations in the tumor suppressor gene, APC, triggered changes in the normal intestinal mucosal epithelium to adenoma. It can be detected in the aberrant crypt foci (ACF), a precursor lesion that occurred early in the beginning of the formation of adenomatous polyps and can only appear in dysplastic lesions [15].

All subjects (100%) in this study had nonsynonymous mutations in APC. Only two patients had adenomas on colonoscopy. One of those had tubulous adenomas with mild dysplasia on colonoscopy and a first-degree relative with CRC. Nonsense mutated APC was found at codons 879, 1095, 1123, which completely stopped glutamine production (Q). Meanwhile, in another patient with villous adenomas and well-differentiated adenocarcinoma, nonsense mutations were found at codons 876, 879, 1096, 1291, 1294, and 1517 that stopped the production of the amino acids glutamine (Q) and arginine (R). Mutations in APC have high-penetrance that can reach 100% for FAP and CRC [16-19]. In contrast to the Japanese population, whose APC mutations scattered at codons 142–1513, subjects in this study had APC mutations occur at codons 876–1517 with mutation cluster regions (MCR) in exons 14–17 [20, 21].

After the normal mucosal epithelium turned into an early adenoma, KRAS mutation occurred subsequently triggering early to intermediate adenoma. In contrast to APC, KRAS can act on nondysplastic ACF precursor lesions [15].

In this study, mutations in the KRAS gene occurred in 14 of 22 samples (63.6%) at 9 codons and were most commonly found in the older age group, locally-advanced stage, well-differentiated/low grade, with positive lymphovascular invasion, and located at the rectum. There were differences in codon location in missense mutation between Jakarta (Indonesia) and the United States population, i.e., codons 13, 14, 34, 58, 59, 146 VS 12, 13, 61, 146 [22]. In addition, nonsense mutations were also found at codon 22 which only occurred in 1 patient. This patient was diagnosed with stage 2A (pT3N0M0) CRC undergoing elective curative resection and 8 cycles of capecitabine adjuvant chemotherapy with complete response. Mutation located in codon 12 has more aggressive behavior than codon 13 because patients were commonly presented in advanced stage [22]. Nevertheless, several cases with metastases involving KRAS mutation in this study were found in 3 of 5 samples without the involvement of codon 12.

KRAS mutation can occur concomitantly with APC mutation leading to increased accumulation of β-catenin in the cytoplasm by destroying its binding to E-cadherin, which increased due to loss of mutated APC degradation function. This causes the Wnt signal to become more active so that motility and cell invasion are more aggressive than normal [15, 18, 21, 23–26]. In CRC, the combination of APC and KRAS mutations (co-occurring mutations) can occur up to 80%, whereas it only occurred in 63.6% of subjects in this study [27].

In this study, patients with APC, TP53, and KRAS mutations were predominantly ≥50 years old, with locally-advanced stage and positive lymphovascular invasion. Two shortest median life expectancy were found in patients with KRAS mutation (Fig 1); in addition, 50% of patients died within six months after therapy (Fig 2).

Before turning into carcinoma, intermediate adenomas differentiate into late adenomas triggered by mutations in the SMAD4, CDC4, and DCC genes [2, 7]. In this study, we found SMAD4 nonsense and missense mutations in 18 of 22 patients (82%).

In ACS theory, late adenomas which developed into carcinomas have mutations in TP53, TGFBR2, BAX, and IGF2R. Mutated TP53 was found in all subjects in this study in the form of nonsense, missense, frameshift, splice-site, and silent mutation. This study’s five most frequently occurred codon locations were 237, 238, 127, G245S, and R248Q. Those are different compared to the world database in The Cancer Genome Atlas Program (TCGA) portal, which stated that the five codon positions with the highest frequency were 175, 282, 248, R273H, and R273C [28].

In contrast to the UK population, in 64% (14 out of 22) subjects, TP53 and KRAS mutations co-occurred [18, 21]. In Indian population, these two combinations were only found in 13 of 112 cases, whereas the study by Timar can occur in up to ~40% [27, 29]. TP53 and KRAS activate different carcinogenesis pathways so that they rarely coexist [30].

Similar to APC and TP53, PIK3CA mutations were found in all subjects (100%) with 9 SNVs. PIK3CA has no role in the aggressive behavior of CRC, yet, when it occurs concurrently with KRAS mutations, evident aggressive behavior will be apparent, especially when it involves exons 9 or 20 or both [31, 32]. In this study, though mutations occurred in exons 2, 3, and 4, aggressive behavior presenting as locally-advanced stage and positive lymphovascular invasion can be found.

Mutations in MLH1 can also occur in non-hereditary/sporadic CRC. The existence of microsatellite instability due to mutations in genes that play roles in the MMR system, such as MLH1, actually provides a good prognosis with a higher survival rate [33]. In this study, the group of cases with MLH1 mutations alone had the highest median life expectancy and had a 30-month survival rate of up to 100%.

Referring to the colorectal neoplasia principle mentioned above, all subjects in this study involved activation of oncogenes (PIK3CA and KRAS) and inactivation of tumor suppressor genes (APC, TP53, and MLH1) and also involved a range of 8–19 mutated genes per person. In this study, mutated APC and KRAS, which are supposed to occur in the early sequence of ACS, supports what Fearon stated about the importance of mutational sequence in determining tumor biologic behavior [1, 2].

We are intensely aware of our study’s limitations regarding small size of samples. Further research is genuinely required to complete the Indonesian profile mapping of colorectal cancer, especially in investigating our unique findings in each of the genes described and the relationship with ethnicities, diets, and lifestyles. This study is also applicable to other type of cancer in Indonesia population.

Nevertheless, this is the first study that fully describes the nature and location of five pathogenic mutated genes of CRC in the Indonesian population with its unique characteristics. Our population is compiled of various ethnicities with diverse diets and lifestyles which may have roles in contributing natures of the Indonesian version of CRC presented in locally-advanced stage with large tumor size and moderate-severe malnutrition status. This study is also the first in the world to examine the co-occurring mutations of APC, TP53, PIK3CA, KRAS, and MLH1.

Different profile of pathogenic mutation in colorectal cancer patients is found in the Indonesian population

Mutated APC, TP53, and PIK3CA occurred in 100% of subjects, while KRAS and MLH1 occurred in 63,6% and 45,4% of subjects

The longest median life expectancy occurred in the group of patients with mutations APC, TP53, PIK3CA, and MLH1 with a 30-month postoperative survival of 100%.

The shortest median life expectancy occurred in the group of patients with APC, TP53, PIK3CA, and KRAS mutations with a 50% life expectancy <6 months post-treatment.

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

25 Feb 2022

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Avaniyapuram Kannan Murugan, M.Phil., Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf  and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide

Additional Editor Comments :

The manuscript received a positive response from the reviewers and needs to be improved prior to publication per the reviewers comments.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The article is the first study to analyze genomic profile of colorectal cancer patients in Indonesian population. The authors utilized an advanced genomics technology and identified mutations. The article is well written, and the data are sufficient to support the conclusion.

Minor things

[1] Typo in page 18 line 12: “underwent neoadjuvar ~” should be “underwent neoadjuvant ~”

[2] What is “Months” in the same page 18 line 12?

Reviewer #2: The authors have herein provided a snapshot of the mutagenic properties of colorectal cancer in a population of patients in Indonesia from 2017-2018.

This clinical synopsis is well-developed and interesting. Further, it is potentially applicable to future studies involving other populations as well as different cancer types, as a number of the predominant pathways and genes indicated here have been shown to play a role in a variety of malignancies across multiple populations.

Minor Revisions:

Page 25:

"(2) at least mutations in 4-5 genes are required for malignant formation; " - Please make this clearer for the reader. Are there specific genes you could identify that would frequently be mutated in order to induce disease, or does this simply refer to 4-5 random mutations?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

5 Mar 2022

Reviewer #1: The article is the first study to analyze genomic profile of colorectal cancer patients in Indonesian population. The authors utilized an advanced genomics technology and identified mutations. The article is well written, and the data are sufficient to support the conclusion.

Minor things

[1] Typo in page 18 line 12: “underwent neoadjuvar ~” should be “underwent neoadjuvant ~”

[2] What is “Months” in the same page 18 line 12?

I already correct it to underwent neoadjuvant. The word “Months” is already deleted, and it was actually part of Figure 2. I already correct it and re upload it as well in Figure 2.

Reviewer #2: The authors have herein provided a snapshot of the mutagenic properties of colorectal cancer in a population of patients in Indonesia from 2017-2018.

This clinical synopsis is well-developed and interesting. Further, it is potentially applicable to future studies involving other populations as well as different cancer types, as a number of the predominant pathways and genes indicated here have been shown to play a role in a variety of malignancies across multiple populations.

Minor Revisions:

Page 25:

"(2) at least mutations in 4-5 genes are required for malignant formation; " - Please make this clearer for the reader. Are there specific genes you could identify that would frequently be mutated in order to induce disease, or does this simply refer to 4-5 random mutations?

“at least mutations in 4-5 genes are required for malignant formation”

I cited this sentence from Reference no.2 (Fearon ER, Vogelstein B. A Genetic Model for Colorectal Tumorigenesis. Cell. 1990;61:759-767).

The study explained that malignancy requires median of four to five allelic losses per tumor.

In earlier years, according to adenoma-carcinoma sequence theory (1990) by Vogelstein, only certain genes are known to be associated in each phase, but nowadays, with more advanced technology, more genes (rather than described in 1990) are involved.

So it is implicitly random, but saying random in this sentence seem inappropriate.

I add the word “any” in "at least mutations in any 4-5 genes are required ……”

Submitted filename: Response to Viewers.docx

Click here for additional data file.

29 Mar 2022

30 Mar 2022

Response to Reviewers

Additional Editor Comments:

1. Modify the original title "Indonesian Genomic Landscape of Pathogenic Mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Colorectal Cancer – How Different We Are from the World" to

"Genomic Landscape of Pathogenic Mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian Colorectal Cancer"

Already Changed – Thank you

2. Table 1: Stage 2A/B/C/ Number 5/1/- Percentage should also follow similar format, i.e: 27/3/-.

Already changed – Thank you

3. All the gene names in: i) Title ii) Table 2 iii) Table 3, 4, 9 iv) Figure legends and Table legends V) Manuscript text to be Italicized.

Already changed – Thank you

Including italicized ALL the gene names in the manuscript.

NB: but I did not highlight all the italicized gene

Submitted filename: Response to Reviewers (2).docx

Click here for additional data file.

4 Apr 2022

Genomic Landscape of Pathogenic Mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian Colorectal Cancer

PONE-D-22-00968R2

Dear Dr. Marbun,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Avaniyapuram Kannan Murugan, M.Phil., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

6 Apr 2022

PONE-D-22-00968R2

Genomic Landscape of Pathogenic Mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian Colorectal Cancer

Dear Dr. Marbun:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Avaniyapuram Kannan Murugan

Academic Editor

PLOS ONE

Table 10

Clinical manifestation of each combination of co-occurring mutations.

	APC + TP53 + PIK3CA + KRAS (Cluster 1)	APC + TP53 + PIK3CA + MLH1 (Cluster 2)	APC + TP53 + PIK3CA + KRAS + MLH1 (Cluster 3)	APC + TP53 + PIK3CA (Cluster 4)
	n = 8	n = 4	n = 6	n = 4
Age (mean) (range)	Mean 48,5±16 (27–75)	Mean 52,3±19 (27–67)	Mean 58,7±13 (40–74)	Mean 56,3±22 (39–87)
≥50 y.o.	4	3	4	2
<50 y.o.	4	1	2	2
Stage
Early	1	0	1	0
Locally-advanced	5	3	4	3
Advanced	2	1	1	1
Lymphovascular invasion
Yes	5	0	4	4
No	3	4	2	0
Tumor location
Group 1	1	1	0	1
Group 2	1	0	3	0
Group 3	6	3	3	3
Grade
Well	6	2	5	0
Moderate	1	0	0	2
Poor	1	2	1	2
Mortality
Yes	4	1	3	3
No	4	3	3	1